Does analysis using “last observation carried forward” introduce bias in dementia research?

If there were a prize for the most inappropriate analytical technique in dementia research, “last observation carried forward” would be the runaway winner. As a society, we have spent millions of dollars on drug research in the hope of improving the care of the estimated 24.3 million people who

[1]  J. Windeler,et al.  Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. , 2001, Statistics in medicine.

[2]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[3]  C. Coffey,et al.  Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF , 2003, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[4]  Hideaki Watanabe,et al.  Points to Consider on Missing Data , 2006 .

[5]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[6]  D. Hogan.  Donepezil for severe Alzheimer's disease , 2006, The Lancet.

[7]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[8]  J. Touchon,et al.  Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period , 2005, Current medical research and opinion.

[9]  K. Davis,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[10]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[11]  David L Streiner,et al.  The Case of the Missing Data: Methods of Dealing with Dropouts and other Research Vagaries , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[12]  C H Mallinckrodt,et al.  ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS , 2001, Journal of biopharmaceutical statistics.

[13]  R. Hills,et al.  DROP-OUT BIAS UNDERMINES FINDINGS OF IMPROVED FUNCTIONALITY WITH CHOLINESTERASE INHIBITORS , 2002 .

[14]  N. Fullwood,et al.  Donepezil for severe Alzheimer's disease , 2006, The Lancet.

[15]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[16]  Geert Molenberghs,et al.  Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory Considerations , 2003, Journal of biopharmaceutical statistics.

[17]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.